Modera Wealth Management LLC Raises Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Modera Wealth Management LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,870 shares of the medical research company’s stock after buying an additional 32 shares during the period. Modera Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $2,394,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Signature Resources Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 318.2% during the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after buying an additional 35 shares during the last quarter. New Millennium Group LLC bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $29,000. Stephens Consulting LLC raised its stake in shares of Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 29 shares during the period. Headlands Technologies LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $32,000. Finally, Bank & Trust Co bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $33,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

TMO has been the topic of a number of analyst reports. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday. Sanford C. Bernstein decreased their price objective on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Redburn Atlantic initiated coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 price objective for the company. Finally, Stephens initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 target price for the company. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Stock Down 0.5 %

Shares of NYSE TMO opened at $554.38 on Monday. The firm’s fifty day moving average is $605.12 and its 200 day moving average is $584.07. Thermo Fisher Scientific Inc. has a 52 week low of $420.21 and a 52 week high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company has a market cap of $211.77 billion, a price-to-earnings ratio of 34.76, a PEG ratio of 3.66 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.69 earnings per share. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.